NPLATE Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NPLATE
| High Confidence Patents: | 4 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for NPLATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NPLATE |
Recent Clinical Trials for NPLATE
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Geropharm | Phase 1 |
| Anjali Sharathkumar | Early Phase 1 |
| Amgen | Early Phase 1 |
Recent Litigation for NPLATE
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. | 2018-04-30 |
Pharmacology for NPLATE
| Mechanism of Action | Thrombopoietin Receptor Agonists |
| Physiological Effect | Increased Megakaryocyte Maturation Increased Platelet Production |
| Established Pharmacologic Class | Thrombopoietin Receptor Agonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NPLATE Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NPLATE Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2018-10-23 | Company disclosures |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2018-10-23 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NPLATE Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2033-03-11 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2034-11-21 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2039-02-26 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2031-04-05 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2035-10-02 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2039-12-21 | Patent claims search |
| Amgen, Inc. | NPLATE | romiplostim | For Injection | 125268 | ⤷ Try a Trial | 2029-05-13 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for NPLATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1746189 | ⤷ Try a Trial |
| Slovakia | 287037 | ⤷ Try a Trial |
| Luxembourg | 91598 | ⤷ Try a Trial |
| Brazil | 9914708 | ⤷ Try a Trial |
| Hong Kong | 1042097 | ⤷ Try a Trial |
| Japan | 2007089586 | ⤷ Try a Trial |
| Norway | 331733 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NPLATE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2009/022 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| PA2009006,C1124961 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| C01124961/01 | Switzerland | ⤷ Try a Trial | FORMER REPRESENTATIVE: BOHEST AG, CH |
| PA2009006 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| CA 2009 00025 | Denmark | ⤷ Try a Trial | |
| 122009000039 | Germany | ⤷ Try a Trial | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| 300398 | Netherlands | ⤷ Try a Trial | DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
